A meta-analysis concluded that for NSCLC with KRAS mutations, ICIs with or without chemotherapy significantly prolonged PFS (HR = 0.58 (0.43–0.78), P = 0.0003) and OS (HR = 0.59 (0.49–0.72), P < 0.00001) compared with chemotherapy monotherapy in both first- and second-line trials [18]. Here, KRAS is linked to non-small cell lung carcinoma.